Comparative Pharmacology
Head-to-head clinical analysis: PEPCID AC versus PEPCID COMPLETE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID AC versus PEPCID COMPLETE.
PEPCID AC vs PEPCID COMPLETE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
Famotidine competitively inhibits histamine at H2-receptors of gastric parietal cells, reducing gastric acid secretion. Calcium carbonate and magnesium hydroxide act as antacids to neutralize existing gastric acid.
20 mg orally twice daily for 12 weeks for erosive esophagitis; 20 mg orally once daily for 4-8 weeks for GERD; 10 mg orally once daily for OTC use for heartburn.
One tablet (famotidine 10mg, calcium carbonate 800mg, magnesium hydroxide 165mg) orally once daily, taken 30 minutes before a meal that causes heartburn.
None Documented
None Documented
2.5-3.5 hours (prolonged in renal impairment, e.g., CrCl <30 mL/min: up to 20 hours)
2.5-3.5 hours (prolonged to 12-20 hours in severe renal impairment, CrCl <10 mL/min).
Renal (65-70% as unchanged drug), hepatic metabolism (minor), biliary/fecal (approx. 30%)
Renal: 65-70% (famotidine unchanged); fecal: 30-35% (as metabolites). Biliary elimination is minimal (<5%).
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist